185 related articles for article (PubMed ID: 12641451)
21. Two polymorphs of a covalent complex between papain and a diazomethylketone inhibitor.
Janowski R; Kozak M; Jankowska E; Grzonka Z; Jaskólski M
J Pept Res; 2004 Oct; 64(4):141-50. PubMed ID: 15357669
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of human cathepsin V.
Somoza JR; Zhan H; Bowman KK; Yu L; Mortara KD; Palmer JT; Clark JM; McGrath ME
Biochemistry; 2000 Oct; 39(41):12543-51. PubMed ID: 11027133
[TBL] [Abstract][Full Text] [Related]
23. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
[TBL] [Abstract][Full Text] [Related]
24. New potent cathepsin G phosphonate inhibitors.
Sieńczyk M; Lesner A; Wysocka M; Legowska A; Pietrusewicz E; Rolka K; Oleksyszyn J
Bioorg Med Chem; 2008 Oct; 16(19):8863-7. PubMed ID: 18805698
[TBL] [Abstract][Full Text] [Related]
25. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.
Löser R; Schilling K; Dimmig E; Gütschow M
J Med Chem; 2005 Dec; 48(24):7688-707. PubMed ID: 16302809
[TBL] [Abstract][Full Text] [Related]
26. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
[TBL] [Abstract][Full Text] [Related]
27. Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode.
Inagaki H; Tsuruoka H; Hornsby M; Lesley SA; Spraggon G; Ellman JA
J Med Chem; 2007 May; 50(11):2693-9. PubMed ID: 17469812
[TBL] [Abstract][Full Text] [Related]
28. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation.
Hou WS; Li Z; Büttner FH; Bartnik E; Brömme D
Biol Chem; 2003 Jun; 384(6):891-7. PubMed ID: 12887056
[TBL] [Abstract][Full Text] [Related]
29. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators.
Somoza JR; Palmer JT; Ho JD
J Mol Biol; 2002 Sep; 322(3):559-68. PubMed ID: 12225749
[TBL] [Abstract][Full Text] [Related]
30. Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography.
Cuerrier D; Moldoveanu T; Inoue J; Davies PL; Campbell RL
Biochemistry; 2006 Jun; 45(24):7446-52. PubMed ID: 16768440
[TBL] [Abstract][Full Text] [Related]
31. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites.
LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS
J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S.
Walker B; Lynas JF; Meighan MA; Brömme D
Biochem Biophys Res Commun; 2000 Aug; 275(2):401-5. PubMed ID: 10964677
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity.
Lecaille F; Choe Y; Brandt W; Li Z; Craik CS; Brömme D
Biochemistry; 2002 Jul; 41(26):8447-54. PubMed ID: 12081494
[TBL] [Abstract][Full Text] [Related]
35. Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.
Frizler M; Schmitz J; Schulz-Fincke AC; Gütschow M
J Med Chem; 2012 Jun; 55(12):5982-6. PubMed ID: 22686657
[TBL] [Abstract][Full Text] [Related]
36. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L.
Brömme D; Klaus JL; Okamoto K; Rasnick D; Palmer JT
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):85-9. PubMed ID: 8670136
[TBL] [Abstract][Full Text] [Related]
37. Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S.
Thurmond RL; Beavers MP; Cai H; Meduna SP; Gustin DJ; Sun S; Almond HJ; Karlsson L; Edwards JP
J Med Chem; 2004 Sep; 47(20):4799-801. PubMed ID: 15369380
[TBL] [Abstract][Full Text] [Related]
38. Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex.
Linnevers CJ; McGrath ME; Armstrong R; Mistry FR; Barnes MG; Klaus JL; Palmer JT; Katz BA; Brömme D
Protein Sci; 1997 Apr; 6(4):919-21. PubMed ID: 9098904
[TBL] [Abstract][Full Text] [Related]
39. Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.
Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Ray JA; Samano V; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
Bioorg Med Chem Lett; 2006 Mar; 16(6):1735-9. PubMed ID: 16376075
[TBL] [Abstract][Full Text] [Related]
40. Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.
Boros EE; Deaton DN; Hassell AM; McFadyen RB; Miller AB; Miller LR; Paulick MG; Shewchuk LM; Thompson JB; Willard DH; Wright LL
Bioorg Med Chem Lett; 2004 Jul; 14(13):3425-9. PubMed ID: 15177446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
